NUBEQA (Bayer Australia Ltd)
Product name
NUBEQA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
182 working days (255)
Active ingredients
darolutamide
Registration type
NCE/NBE
Indication
NUBEQA (tablets) is indicated for the treatment of patients with non-metastatic castration resistant prostate cancer (nmCRPC).